_version_ 1785090652155936768
author Atluri, Himachandana
Patel, Keyur
Routbort, Mark
Oran, Betul
Issa, Ghayas
Short, Nicholas
Daver, Naval
Kadia, Tapan
Ravandi, Farhad
E. Champlin, Richard
J. Shpall, Elizabeth
Pierce, Sherry
Kanagal-Shamanna, Rashmi
Young Ok, Chi
Tang, Guilin
Wang, Sa
Luthra, Rajyalakshmi
Lasrey, Audrey
Nadorp, Bettina
Chroni, Antonia
Eisfeld, Ann-Kathrin
Aifantis, Ioannis
Medeiros, L. Jeffrey
Dinardo, Courtney
Loghavi, Sanam
author_facet Atluri, Himachandana
Patel, Keyur
Routbort, Mark
Oran, Betul
Issa, Ghayas
Short, Nicholas
Daver, Naval
Kadia, Tapan
Ravandi, Farhad
E. Champlin, Richard
J. Shpall, Elizabeth
Pierce, Sherry
Kanagal-Shamanna, Rashmi
Young Ok, Chi
Tang, Guilin
Wang, Sa
Luthra, Rajyalakshmi
Lasrey, Audrey
Nadorp, Bettina
Chroni, Antonia
Eisfeld, Ann-Kathrin
Aifantis, Ioannis
Medeiros, L. Jeffrey
Dinardo, Courtney
Loghavi, Sanam
author_sort Atluri, Himachandana
collection PubMed
description
format Online
Article
Text
id pubmed-10429204
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104292042023-08-17 P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES Atluri, Himachandana Patel, Keyur Routbort, Mark Oran, Betul Issa, Ghayas Short, Nicholas Daver, Naval Kadia, Tapan Ravandi, Farhad E. Champlin, Richard J. Shpall, Elizabeth Pierce, Sherry Kanagal-Shamanna, Rashmi Young Ok, Chi Tang, Guilin Wang, Sa Luthra, Rajyalakshmi Lasrey, Audrey Nadorp, Bettina Chroni, Antonia Eisfeld, Ann-Kathrin Aifantis, Ioannis Medeiros, L. Jeffrey Dinardo, Courtney Loghavi, Sanam Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429204/ http://dx.doi.org/10.1097/01.HS9.0000969236.15137.e3 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Atluri, Himachandana
Patel, Keyur
Routbort, Mark
Oran, Betul
Issa, Ghayas
Short, Nicholas
Daver, Naval
Kadia, Tapan
Ravandi, Farhad
E. Champlin, Richard
J. Shpall, Elizabeth
Pierce, Sherry
Kanagal-Shamanna, Rashmi
Young Ok, Chi
Tang, Guilin
Wang, Sa
Luthra, Rajyalakshmi
Lasrey, Audrey
Nadorp, Bettina
Chroni, Antonia
Eisfeld, Ann-Kathrin
Aifantis, Ioannis
Medeiros, L. Jeffrey
Dinardo, Courtney
Loghavi, Sanam
P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
title P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
title_full P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
title_fullStr P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
title_full_unstemmed P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
title_short P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
title_sort p583: prognostic implications of wt1 mutations in patients with de novo and relapsed acute myeloid leukemia in the era of novel targeted therapies
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429204/
http://dx.doi.org/10.1097/01.HS9.0000969236.15137.e3
work_keys_str_mv AT atlurihimachandana p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT patelkeyur p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT routbortmark p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT oranbetul p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT issaghayas p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT shortnicholas p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT davernaval p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT kadiatapan p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT ravandifarhad p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT echamplinrichard p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT jshpallelizabeth p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT piercesherry p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT kanagalshamannarashmi p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT youngokchi p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT tangguilin p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT wangsa p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT luthrarajyalakshmi p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT lasreyaudrey p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT nadorpbettina p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT chroniantonia p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT eisfeldannkathrin p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT aifantisioannis p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT medeirosljeffrey p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT dinardocourtney p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies
AT loghavisanam p583prognosticimplicationsofwt1mutationsinpatientswithdenovoandrelapsedacutemyeloidleukemiaintheeraofnoveltargetedtherapies